Hornhahn9065

Notably, miR-101a serum levels showed good sensitivity and specificity for diagnosis of HNSCC. CONCLUSIONS The results showed that HNSCC patients had higher tissue expression of miR-372 and lower expression of miR-101a. Also, serum levels of miR-101a were lower in HNSCC patients. We observed that miR-101a had good sensitivity and specificity for diagnosis of HNSCC. The present study suggested that miR-101a could be a potential biomarker for HNSCC.BACKGROUND Hematological reference interval is the range between two reference values that are used for inter-pretation of test results. It is affected by various physiological and environmental factors; thus, locally derived hematological reference values are essential for accurate diagnosis and treatment of patients. The main goal of this study was to establish hematological reference intervals for healthy adults at Kemise, Northeast Ethiopia. METHODS A cross-sectional study was conducted from January to April, 2019, with 170 male and 159 female apparently healthy adult blood donors at Kemise Blood Bank. A structured pretested questionnaire was used for socio demographic and clinical data collection. About 4 mL of blood was collected in an EDTA test tube and analyzed using Sysmex XP-300 to enumerate the hematological parameters. The data were collected and entered into Epi-Inf7 and then transferred to SPSS version 20 for analysis. Dixon and Reed 1/3 rule was used for outlier detection. Mann-Whitney U test wfrican countries or in Caucasian population, and in text books. The RBC, PCV, and Hgb reference intervals were different in gender. So, using of locally determined reference interval is essential.BACKGROUND Hematology analysis is a common test among patients in hospital. However, manual verification of hematology analysis is time consuming and tedious, with variation between inter-individual laboratory workers. This study was to establish and validate a set of autoverification rules for hematology analysis in the department of laboratory medicine, Zhongshan Hospital of Sun Yatsen University. METHODS Hematology analysis was measured by a Sysmex XN-9000 hematology system in the Department of Laboratory Medicine, Zhongshan Hospital of Sun Yatsen University. SYSMEX Laboman EasyAccess 6.0 and the laboratory information system were used to construct the algorithm and design the autoverification rules of hematology analysis according to Clinical and Laboratory Standards Institute document Auto 10A and 41 rules of Hematology Review Criteria. The laboratory turnaround time (TAT), autoverification pass rates, false positive, false negative, and the average error rate were verified after implementing autoverification rules. RESULTS Approximate 1,300 specimens were collected daily and transferred to our laboratory for hematology analysis; that is necessary to build a database and to design autoverification rules. The average autoverification passing rate was 81%; the false positive rate was 13.6%; the false negative rate and the average error rate was nearly zero, indicating that incorrect reports were almost eliminated. Moreover, since implementing autoverification, the TAT was reduced by 27.0% in in-patient reports, by 21.9% in out-patient reports, and by 39.0% in emergency reports, which enhanced the productivity in our laboratory. CONCLUSIONS Our laboratory accelerated verification and decreased TAT and the odds of human review errors in the released results since implementing the autoverification. Thus, we can save more time and concentrate on verifying the abnormal results and processing emergency tests.BACKGROUND Fecal calprotectin is an excellent biomarker for distinguishing inflammatory bowel disease from irritable bowel syndrome and for evaluation of disease activity in Crohn's disease and ulcerative colitis. The aim of this work was to evaluate the analytical performance of a new flow immune chromatography assay by comparing it to our standardized laboratory gold standard system. METHODS A total of 100 stool samples sent for routine calprotectin level measurements were analyzed by the Liaison XL system and the QuantOn Cal assay simultaneously using the same cutoff values for both assays. Performance of the QuantOn Cal assay was assessed by calculating sensitivity, specificity, and accuracy. RESULTS Compared with the gold standard, the sensitivity, specificity, and accuracy of the QuantOn Cal assay were 98.7%, 76.2%, and 94.0%, respectively. Furthermore, linear correlation of calprotectin levels between the two assays were found to be significant by Pearson's correlation coefficient test (r = 0.82, p-values less then 0.0001). CONCLUSIONS The QuantOn Cal assay demonstrated good performance, both qualitative and quantitative when compared to the Liaison XL system. This novel and rapid assay is well suited for measuring fecal calprotectin as a point of care or home-based assay when laboratory services are limited or not available.BACKGROUND Published data regarding associations between the microRNA-146a polymorphism and the risk of gastric cancer are inconclusive. This study aims at evaluating the genetic risk of microRNA-146a polymorphism in gastric cancer. METHODS A systematic literature search was carried out in Pubmed, Medline (Ovid), Embase, CBM, CNKI, Weipu, and Wanfang databases, covering all available publications (last search was performed on Apr 15th, 2019). Statistical analysis was performed using Revman 5.2 and STATA 10.1 software. RESULTS A total of 5,017 cases and 4,869 controls in 14 case-control studies were included in this meta-analysis. No significant association between microRNA-146a polymorphism and gastric cancer risk was observed in all kinds of genetic models (homozygote genetic model CC vs. GG OR = 0.96, 95% CI = 0.81 - 1.15, p = 0.66; the heterozygote genetic model CG vs. GG OR = 0.94, 95% CI = 0.86 - 1.02, p = 0.15; the recessive genetic model CC vs. CG + GG OR = 0.98, 95% CI = 0.91 - 1.05; the dominant genetic model CC + CG vs. GG OR = 0.94, 95% CI = 0.86 - 1.01, p = 0.1, p = 0.55; and the allele genetic model C vs. G OR = 0.98, 95% CI = 0.89 - 1.06, p = 0.58). In subgroup analysis, the C allele may be a protective factor for gastric cancer development in the analysis of the dominant genetic model (CC + CG vs. GG) in HCC studies (OR = 0.90, 95% CI = 0.83 - 0.98, p = 0.02) but a risk factor in Japanese when calculated with the recessive genetic model (CC vs. CG + GG) (OR = 1.19, 95% CI = 1.02 - 1.40, p = 0.03). CONCLUSIONS Based on our meta-analysis, the microRNA-146a polymorphism is unlikely to be a risk factor for gastric cancer in overall population.BACKGROUND Hypocholesterolemia has been reported to be associated with cancer risk and progression. The aim of this retrospective study was to investigate the prognostic value of cholesterol levels in patients with multiple myeloma (MM). METHODS A total of 153 patients newly diagnosed with MM were retrospectively enrolled. The relationship between cholesterol levels and clinical characteristics was evaluated. SQ22536 The prognostic value of cholesterol levels was explored. RESULTS The levels of low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and triglycerides (TC) were significantly lower in MM patients (p less then 0.001). What is more, multivariate analyses showed that low TC and LDL-c levels were independent predictors of a better OS (overall survival; HR = 6.893 and 0.204; CI = 1.135 - 41.868 and 0.045 - 0.930, p = 0.036 and 0.040) and PFS (progression-free survival; HR = 7.416 and 0.216; CI = 1.365 - 40.290 and 0.047 - 0.999, p = 0.020 and 0.049). CONCLUSIONS Serum cholesterol levels in MM patients were low, and TC and LDL-c levels could be used as prognostic markers for MM patients.BACKGROUND The aim of the study was to explore the expression level of miRNA-30 expression in patients with non-small cell lung cancer (NCLC) and analyze its correlation with clinicopathological features and prognosis. METHODS Preoperative serum samples and paracancerous tumor-free tissues of 108 patients with NSCLC treated in our hospital as well as serum samples of 108 healthy subjects were collected from April 2015 to May 2018. The expression levels of miRNA-30 in tissue samples were detected by in situ hybridization and that of miRNA-30 mRNA in serum samples by real-time quantitative PCR (RT-qPCR). The difference in miRNA-30 expression in tumor-free tissues of NSCLC patients and NSCLC tissues of each stage was measured. The miRNA-30 mRNA levels in NSCLC patients was compared with those in healthy subjects. All subjects were divided into low-expression group ( 0.05), but correlated with lymph node metastasis, tumor size, TNM stage, and degree of differentiation (p less then 0.05). The median overall survival of the miRNA-30 low expression group was 23.0 months, which was shorter than the 36.0 months of high expression group, and the difference was statistically significant (p less then 0.05). CONCLUSIONS miRNA-30 is lowly expressed in NSCLC patients and participates in the development of NSCLC. Moreover, NSCLC patients with low expression show poor prognosis. Thus, miRNA-30 features potential as a marker for NSCLC screening and prognosis prediction.BACKGROUND Tropomyosin alpha-1 chain (TPM1) is a member of the tropomyosin family and the expression of TPM1 is found to be dysregulated in various tumors. The present study aimed to investigate the clinical performance and significance of TPM1 in gastric cancer. METHODS First, the levels of TPM1 mRNA and protein were detected through real-time polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC) respectively. The correlation between TPM1 expression and clinicopathological variables was analyzed. Then, receiver operating characteristic (ROC) curve was applied to determine the diagnostic performance of TPM1 in gastric cancer. Finally, overall survival analysis was carried out using Kaplan-Meier method in order to determine the prognostic performance of TPM1 in gastric cancer. RESULTS Compared with the controls, TPM1 mRNA and protein expression levels were significantly downregulated in patients with gastric cancer. Downregulation of TPM1 was associated with depth of invasion and tumor node metastasis (TNM; p = 0.0030 and 0.0175, respectively). Furthermore, TPM1 might be a novel predictive biomarker for gastric cancer with an area under curve (AUC) of 0.8327. Overall survival analysis indicated that low TPM1 expression predicted poor survival (log-rank test, p = 0.0058). CONCLUSIONS TPM1 might be a novel predictive diagnostic and prognostic biomarker for gastric cancer (95% con-fidence interval = 0.7705 - 0.8949, p less then 0.0001).BACKGROUND Immunocompromised patients are at increased risk of morbidity and mortality due to transfusion transmitted cytomegalovirus (CMV) infections. To avoid or minimize such risk, clinicians working in the field continually monitor the changing epidemiology of CMV infections. MATERIALS AND METHODS A total of 234,192 blood donations obtained from 44,779 donors were tested. CMV seroprevalence and antibody conversion rates were determined over a 3-year period. RESULTS A significant percentage (37.5%) of all male and female blood donors tested seropositive. Both age and gender were risk factors for CMV infection. A total of 177 seroconversions (0.4% of donors) were identified. The highest antibody conversion rate occurred among men between 30 and 39 years of age; women did not experience a similar peak in antibody conversion rate. Approximately 10% of infected blood donors were identified by CMV DNA testing prior to seroconversion. CONCLUSIONS The high rates of seroprevalence and seroconversion and the identification of a significant number of CMV DNA-positive (infected) blood donors prior to seroconversion indicate that the routine testing of blood samples for CMV DNA could reduce the potential risk of CMV transmission to high-risk patients.